Composition GHK-Cu Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions For qualified research professionals and institutional laboratories
Please visit hpplans.com/provider-online-courses to access the Annual Training for Network Providers (ATP) eLearning course
Utilizing patented vela and elos technology, the VelaShape III laser is the first and leading FDA-cleared non-invasive medical solution for circumferential reduction and the first FDA class II cleared platform for cellulite reduction
The trial has an estimated completion date in H1 2023 just like the SURMOUNT-4 study (NCT04660643) of Tirzepatide in obesity from Eli Lilly
Future research should focus on developing strategies for selective targeting to minimize effects on normal tissues, understanding mechanisms of resistance and ways to overcome them, and optimizing combination therapies with chemotherapy, radiotherapy, or immunotherapy to enhance efficacy
Diabetes Res Clin Pract 186:109806
